The Road to Market Access
|
|
- Oswald Barry Goodman
- 6 years ago
- Views:
Transcription
1 The Road to Market Access From Concept to End of Lifecycle April 2017 CAHR MA 101
2 ROUBAIX STRATEGIES INC. Roubaix [ru-bae]: The Paris-Roubaix is one of the most difficult single-day professional cycling races in the world. At more than 250km, cyclists must transition between paved roads and centuriesold cobblestone paths. Just like market access in Canada, negotiating these challenging conditions requires strategic planning, careful preparation, superior teamwork, and a bit of courage.
3 The Road to Market Access 1. Overview 2. Regulatory 3. Pricing 4. Budgets 5. Health Technology Assessment (HTA) 6. Patients 7. Pan-Canadian Pharmaceutical Alliance (pcpa) 8. Private Drug Plans
4 OVERVIEW
5 Access to Innovative Medicines in Canada: From Concept to Market PMPRB / PRICING HC HTA pcpa PLAs pcpa Renegotiations? LOE Thousands of candidates Pre-Clinical Clinical (Ph1-3) Public Drug Plan Reimbursement Private Drug Plan Reimbursement Roubaix Strategies Inc. All rights reserved. 20-YEAR PATENT TERM 8-12 YEARS 12-8 YEARS PMPRB = Patented Medicines Prices Review Board; HC = Health Canada; pcpa = pan-canadian Pharmaceutical Alliance PLAs = Product Listing Agreements; LOE = Loss of Exclusivity; HTA = Health Technology Assessment;
6 Access to Innovative Medicines is Generally Longer in Canada vs. Countries with Comparable Healthcare Systems Source: Innovative Medicines Canada, Access to New Medicines in Public Drug Plans: Canada and Comparable Countries, 2016 Annual Report
7 Market Access: The Most Important Function in Canadian Drug Reimbursement Specialty Drugs Account for 80% of New HTA Submissions No Amount of Marketing Can Overcome a lack of Drug Plan Funding Stakeholder Description Practitioners: Physicians FP/GPs 1, specialists, residents Pharmacists Hospital/community pharmacy Nurses RNs, nurse practitioners Payers/Managers: Government Drug Plans Drug Approval/Advisory Groups Regional Health Authorities Private Drug Plans Consumers: Consumers/Disease Groups Federal/provincial/territorial (includes cancer agencies) pcpa, Common Drug Review, pcodr 2 and government drug expert groups Different provincial models (e.g. Alberta Health Services, LHINs 3 ) Source: IMS Brogan 1 Family physicians/general practitioners and others who prescribe drugs in different settings, including the hospital environment 2 pan-canadian Oncology Drug Review 3 Local Health Integration Networks in Ontario 4 Includes organizations set up to advise insurers/employers such as pharmacy benefit managers, benefit advisors Insurers, employers and other third parties Consumers at large, and organizations (seniors /women s groups, disease associations, consumer groups) Total Courtesy Janssen Pharmaceuticals
8 REGULATORY
9 By the Time a Patented Drug/Biologic is Approved by Health Canada, it has ~10 years of Market Exclusivity PMPRB / PRICING HC HTA pcpa PLAs pcpa Renegotiations? LOE Thousands of candidates Pre-Clinical Clinical (Ph1-3) Public Drug Plan Reimbursement Private Drug Plan Reimbursement Roubaix Strategies Inc. All rights reserved. 20-YEAR PATENT TERM 8-12 YEARS 12-8 YEARS PMPRB = Patented Medicines Prices Review Board; HC = Health Canada; pcpa = pan-canadian Pharmaceutical Alliance PLAs = Product Listing Agreements; LOE = Loss of Exclusivity; HTA = Health Technology Assessment;
10 Health Canada Reviews Health Canada reviews Drug Safety, Efficacy, and Manufacturing Quality NOC = Notice of Compliance; NOC/c = NOC with Conditions Product Monographs provide information on approved indications for use, (claims that can be made by the manufacturer) clinical data, safety data Regulatory Transparency is Evolving HC reviewer reports: CADTH requires and is granted access to review these. List of drug and health product submissions under review (SUR) has been posted since April 2015 On March 9, 2017 proposes to proactively make certain submitted clinical information publicly available following completed reviews
11 PRICING WHEN DOES IT BEGIN? AND WHAT IS CONSIDERED?
12 Pharmaceutical Pricing Occurs in a Global Market Which Affects Decisions Made Here Canada represents ~2% of global pharmaceutical market1 Source: PMPRB 2015 Annual Report (published 2016)
13 Canadian Patented Medicines Drug Price YOY Changes Consistently Below the CPI CPI = Consumer Price Index Source: PMPRB 2015 Annual Report (published 2016)
14 Canadian Patented Medicines Drug Prices are at Par or Lower Than Three Comparator Countries Source: PMPRB 2015 Annual Report (published 2016)
15 There is Growing Attention on Canadian (and Global) Drug Pricing PMPRB is considering unprecedented changes to its scope and mandate, asking: Is PMPRB relevant in today s market? Is their mandate appropriate for ensuring non-excessive pricing? Does it need to change to address questions of affordability?
16 BUDGETS EVEN BEFORE SUBMISSIONS ARE MADE FOR DRUG REIMBURSEMENT, BUDGET IMPACT AND VALUE FOR MONEY ARE THE GROWING FOCUS OF DRUG PLANS
17 Drug Costs Are Rising Slightly, But Their Share of Total Health Costs is Diminishing % 16.8% % 16.4% % $B % Drugs 16.0% % 15.6% % f 2015f 15.2% 15.0% Total Health Expenditures Total Drug Expenditures Drugs % Share of Total Health Expenditures 1. Source: CIHI,NHEX database, posted at Industry Canada, 2016.
18 Public Healthcare Spending Close to 40% of Program Spend The proportion of government expenditures allocated to healthcare has stabilized over the last decade. Note Financial Management System data is estimated for 2009 to Sources National Health Expenditure Database, Canadian Institute for Health Information; Financial Management System, Statistics Canada; provincial public accounts, budgets, main estimates.
19 Spending on Healthcare Continues to Grow
20 Provinces Continue to Struggle With Debt Courtesy Janssen Pharmaceuticals
21 HEALTH TECHNOLOGY ASSESSMENT
22 The Road to Pharmaceutical Market Access in Canada is Complex, Travelling Through Various Channels to Patients Health Canada Approves Product for Sale Notice of Compliance (NOC) Manufacturer Reimbursement Submissions Pre-NOC? Requirements vary by type of drug plan Public Rest of Canada (ROC) Public (Quebec) CADTH/pCODR before public drug programs will review & reimburse INESSS Reviews before Quebec will reimburse Pan-Canadian Pharmaceutical Alliance (Negotiate Letters of Intent) Provincial, Territorial & Federal Public drug plans (Negotiate Reimbursement Agreements) Criteria Harmonization? Variability? Listing Delays? Value-Based Agreements? Private Insurers Reimbursement can vary by plan
23 In Canada, There is a Gap Between Drug Approval and Public Reimbursement Percentage of new medicines launched and publicly reimbursed by country (IMC 2016 Annual Report) Percentage of new biologic medicines launched and publicly reimbursed by country (IMC 2016 Annual Report) IMC: ACCESS TO NEW MEDICINES IN PUBLIC DRUG PLANS: Canada and Comparable Countries (2016)
24 PATIENTS
25 Formal Patient Input Occurs For HTA Reviews; Yet Engagement Extends Throughout Drug Lifecycle PMPRB / PRICING HC HTA pcpa PLAs pcpa Renegotiations? LOE Thousands of candidates Pre-Clinical Clinical (Ph1-3) Public Drug Plan Reimbursement Private Drug Plan Reimbursement Roubaix Strategies Inc. All rights reserved. 20-YEAR PATENT TERM 8-12 YEARS 12-8 YEARS PMPRB = Patented Medicines Prices Review Board; HC = Health Canada; pcpa = pan-canadian Pharmaceutical Alliance PLAs = Product Listing Agreements; LOE = Loss of Exclusivity; HTA = Health Technology Assessment;
26 PCPA
27 Reimbursement Strategy & Negotiation Development Timelines HTA Submission Provincial Submissions pcpa Negotiations -2yrs -3-6 mos. NOC +3-6 mos. +6 mos. +1 yr. Pre-sub strategy Process HTA Recommendation Provincial Listings Reimbursement strategy considerations Value Proposition Anticipated market dynamics and competitive set Commercial strategy Payer environment Health Economic Modeling Data gaps/plans to address Courtesy Janssen Pharmaceuticals 27 27
28 Negotiation Timeframes Can Vary, and Closed Deals May Be Revisited as Market Changes PMPRB / PRICING HC HTA pcpa PLAs pcpa Renegotiations? LOE Thousands of candidates Pre-Clinical Clinical (Ph1-3) Public Drug Plan Reimbursement Private Drug Plan Reimbursement Roubaix Strategies Inc. All rights reserved. 20-YEAR PATENT TERM 8-12 YEARS 12-8 YEARS PMPRB = Patented Medicines Prices Review Board; HC = Health Canada; pcpa = pan-canadian Pharmaceutical Alliance PLAs = Product Listing Agreements; LOE = Loss of Exclusivity; HTA = Health Technology Assessment;
29 The pcpa is Facing Greater Numbers of Drugs Waiting for Negotiations pcpa Negotiation Mix: As of Dec 31, % of drugs under negotiations with the pcpa are Specialty Drugs. Currently ~40+ Drugs in Active Negotiations More waiting Wait-times are going up: some estimates indicate ~ three months Unclear Operating Framework for pcpa s Mandate and Objectives Specialty drugs are generally defined as those products with an annual cost > $10,000
30 4 of 10 Drugs Remain in pcpa Negotiations Six Months After Engagement 100% % of Drugs Remaining In pcpa Negotiations After Index Date 22 drugs 24 drugs 22 drugs 75% 50% 25% 0% 75% 68% 64% 45% 46% 41% 23% 25% 23% 14% 8% 5% INDEX MONTH 3 MONTHS 6 MONTHS 9 MONTHS 12 MONTHS* 18 MONTHS* Sep 2015 Dec 2015 Mar 2016 *12 & 18 months: three and one drug respectively ** As of December 31, 2016 Roubaix Strategies Inc contact: JPD@roubaixstrategies.com Now 43 drug products in Active Negotiations**
31 Are pcpa Objectives Clear? pcpa Objectives (Website): 1. Increase access to drug treatment options; 2. Achieve lower drug costs and consistent pricing, and 3. Improve consistency of coverage criteria across Canada.
32 PRIVATE DRUG PLANS
33 The Road to Pharmaceutical Market Access in Canada is Only Becoming More Complex Health Canada Approves Product for Sale Notice of Compliance (NOC) Manufacturer Reimbursement Submissions Pre-NOC? Requirements vary by type of drug plan Public Rest of Canada (ROC) Public (Quebec) CADTH/pCODR before public drug programs will review & reimburse INESSS Reviews before Quebec will reimburse Private Insurers Reimbursement can vary by plan Pan-Canadian Pharmaceutical Alliance (Negotiate Letters of Intent) Provincial, Territorial & Federal Public drug plans Employer Drug Plans Coordination? (Negotiate Reimbursement Agreements) Criteria Harmonization? Variability? Listing Delays? Value-Based Agreements? Delays? Caps? Prior-Authorizations? Pharmacy Networks?
34 The Private Stakeholders Insurers 3 PBMs ~3K Benefit Advisors Payer ~500K Plan Sponsors ~23M Plan Members Courtesy Janssen Pharmaceuticals
35 Payer value expectations increase with shifting cost: But Cost Management Actions Should Differ Based on Volume and Risk 35.0% 30.0% 25.0% Private Plan Specialty Drug Expenditure 24.2% 29.9% Public Plan Specialty Drug Expenditure 29.2% 20.0% 15.0% 13.2% <3% of claimants 16.4% 10.0% 5.0% 0.0% Sources: ESC Drug Trend Reports (2014, 2016); PMPRB, NPDUIS
36 Private Plans Talk About Integrating into the Public Reimbursement Process. It is Plausible? CDR REVIEW PCPA NEGOTIATIONS UP TO 15 SEPARATE FPT NEGOTIATIONS HOW MANY PRIVATE PLAN NEGOTIATIONS? The pcpa does not negotiate product reimbursement. It negotiates the intention for product reimbursement On market ESTIMATED MONTHS AFTER HEALTH CANADA APPROVAL Roubaix Strategies Inc. contact: JPD@roubaixstrategies.com
37 The Current Landscape ueconomic slowdown + Chronicity of disease + Cost of meds = pressure on employers = pressure on Insurers = pressure on Pharma manufacturers Prior/Special Authorization Step Edits Mandatory Generic/Therapeutic substitution Tiered formularies Case management Preferred pharmacy networks upayers seeking SUSTAINABILITY = OPPORTUNITY for pharmaceutical manufacturers
38 Private Insurance Coverage for 23 Million Canadians SSQ and Desjardins 10% Others 11% Sun Life 18% GreenShield 4% Pacific Blue Cross 6% Great West Life 18% Alberta Blue Cross 7% ClaimSecure 5% Medavie Blue Cross 3% Manulife 19% Source: Janssen Pharmaceuticals
National Pharmacare: What Do We Know? What Do We Need to Know? W. Neil Palmer
Healthy Canada Conference 2017: Access to Affordable Medicines Toronto April 2017 National Pharmacare: What Do We Know? What Do We Need to Know? W. Neil Palmer Why National Pharmacare? 1. Universal / comprehensive
More informationCompass. 2 ND Edition. Annual Public Drug Plan Expenditure Report 2013/14
Compass 2 ND Edition Annual Public Drug Plan Expenditure Report 2013/14 Published by the Patented Medicine Prices Review Board May 2016 NPDUIS CompassRx: Annual Public Drug Plan Expenditure Report, 2 nd
More informationInsurance & Medication Access
Insurance & Medication Access Ontario Rheumatology Association 12th Annual Meeting JW Marriott The Rosseau Muskoka May 25, 2013 Suzanne Lepage, Private Health Plan Strategist Learning Objectives Understand
More informationSPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS
SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS SPECIALTY PHARMA DRIVING THE EMERGENCE OF ACCESS HUBS FOR PRIVATE PAYERS The rising cost of drugs, fuelled by the growing specialty
More informationPresident s Office Bureau du Président
President s Office Bureau du Président September 28, 2018 Advisory Council on the Implementation of National Pharmacare Secretariat Brooke Claxton Building 70 Colombine Driveway Ottawa, ON K1A 0K9 Email:
More informationIMS Brogan Private Drug Plan Drug Cost Forecast Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies
IMS Brogan Private Drug Plan Drug Cost Forecast 2013-2017 Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies Overview 1. Who are Rx&D and IMS Brogan? 2. Environment 3. Background 4.
More informationHTA and Submissions. Ferg Mills, Angela Rocchi April 5, Agenda
HTA and Submissions Ferg Mills, Angela Rocchi April 5, 2017 Agenda The Decision Problem Role of HTA bodies in Canada CADTH, pcodr and INESSS Overview of the elements of the HTA submission Clinical package
More information250 Dundas Street West, Suite 500 Toronto ON, M5T 2Z5 (Contact)
Feedback submitted to the Patented Medicines Pricing Review Board from the Multiple Sclerosis Society of Canada related to Excessive Drug Pricing in Canada Deadline: Monday, October 24, 2016 Submitted
More informationTowards Implementation of National Pharmacare. Discussion Paper
Towards Implementation of National Pharmacare Discussion Paper Publication date: June 2018 This publication may be reproduced for personal or internal use only without permission provided the source is
More informationDemonstrating Value of Medicines Through Health Economic and Outcomes Evidence
Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence Eleni Samaras Allen, PharmD March 22, 2016 Kissimmee, FL Disclaimer The views and opinions expressed in the following PowerPoint
More informationSession 88 PD, Drug Claim Management. Presenters: Daniel Berty Suzanne Lepage. SOA Antitrust Disclaimer SOA Presentation Disclaimer
Session 88 PD, Drug Claim Management Presenters: Daniel Berty Suzanne Lepage SOA Antitrust Disclaimer SOA Presentation Disclaimer Industry pooling solution Outcomes and opportunities Dan Berty, Executive
More informationIntroducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market
Introducing Manulife DrugWatch Applying rigorous oversight to help ensure value for money in a dramatically changing drug market The drug market in Canada is changing rapidly and dramatically Many Canadians
More informationPHARMACARE AND OTHER DRUG PROGRAMS
7 PHARMACARE AND OTHER DRUG PROGRAMS BACKGROUND 7.1 The Department of Health (DOH) manages Nova Scotia s publicly funded prescription drug programs. The net cost of these programs to the DOH has increased
More informationFair Drug Prices for Nova Scotians
Fair Drug Prices for Nova Scotians September 2010 Fair Drug Prices for Nova Scotians September 2010 The Problem Nova Scotians pay too much for prescription drugs. In Nova Scotia, we pay more for generic
More informationPharmaceutical Strategy Policy Options for the Government of Northwest Territories 1
1 Executive Summary Based on a request from the Government of the Northwest Territories (GNWT), Alberta Blue Cross is pleased to provide the following information and analysis to support the Department
More informationBetter Pharmacare for Patients: Evaluating Policy Options
Better Pharmacare for Patients: Evaluating Policy Options A Report from the Pharmacare Working Group The Pharmacare Working Group is comprised of representatives from the Canadian Pharmacists Association
More informationFORMULARIES IN CANADA PART 1: GENERAL OVERVIEW
ALIGNMENT AMONG PUBLIC FORMULARIES IN CANADA PART 1: GENERAL OVERVIEW Published by the Patented Medicine Prices Review Board October 2017 Alignment Among Public Formularies in Canada Part 1: General Overview
More information2. Risk exists, government intervention is required, regulation is best alternative
Introduction & Background Response to the Health Canada Consultation Document This response to the consultation document has been prepared by Neil Palmer, Founder and Principal Consultant of PDCI Market
More informationTABLE OF CONTENTS 1. INTRODUCTION GUIDING PRINCIPLES ANALYSIS AND RECOMMENDATIONS...4
TABLE OF CONTENTS 1. INTRODUCTION...1 2. GUIDING PRINCIPLES...3 3. ANALYSIS AND RECOMMENDATIONS...4 A. ENSURING SAFETY AND ENCOURAGING INNOVATION... 4 a.1 Head-to-head Clinical Trials... 4 a.2 Approval
More informationMarc Claussen, Chiesi USA, Director, Market Access. Donna White, Chiesi USA, Sr. Director, Contracting and Compliance
Marc Claussen, Chiesi USA, Director, Market Access Donna White, Chiesi USA, Sr. Director, Contracting and Compliance The views/observations expressed in this presentation are the personal views/observations
More informationKEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)
The Texas Association of Health Plans Representing health insurers, health maintenance organizations, and other related health care entities operating in Texas. KEEPING PRESCRIPTION DRUGS AFFORDABLE: The
More informationSummary of Recommendations: Moving from Principles to Policies
Summary of Recommendations: Moving from Principles to Policies 15 July 2015 Steven G. Morgan, PhD, University of British Columbia Danielle Martin, MD, CCFP, MPP, University of Toronto Marc-André Gagnon,
More informationRecommendations on the Proposed Amendments to the Patented Medicines Regulations
Recommendations on the Proposed Amendments to the Patented Medicines Regulations February 14, 2018 Endorsed by: Proposed Amendments to the Patented Medicines Regulations Patient group response February
More informationCLHIA Briefing: Canadian life and health insurance industry agreement to protect Canadians' drug coverage
CLHIA Briefing: Canadian life and health insurance industry agreement to protect Canadians' drug coverage April 4, 2011 Agenda Rationale for this agreement Benefits for Canadians How the agreement works
More informationINTERNATIONAL TRENDS SERIES
INTERNATIONAL TRENDS SERIES Issue 5: Private Payer Exclusivity Agreements June 8, 2015 Copyright 2015 by PDCI Market Access Inc. The information presented is property of PDCI Market Access. Unauthorized
More informationLindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy
Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES
More informationPHARMACY BENEFIT MANAGER (PBM)
PHARMACY BENEFIT MANAGER (PBM) Presentation by: Pantea Ghasemi, USC Pharm.D. Candidate of 2015 Mentor: Dr. Craig Stern, Pro Pharma Consultants Inc. April 3, 2015 OBJECTIVES 1. Define PBM 2. Discuss Service
More informationIndividual Patient Funding Programs: Policy Considerations
Individual Patient Funding Programs: Policy Considerations May 7, 2013 Presented by: Glenn McAuley, Senior Pharmacist, Drug Programs Services, Ontario Public Drug Programs Scott Gavura, Director, Provincial
More informationThe U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use. Presented by Daniel Tomaszewski Pharmd, PhD
The U.S. Healthcare System: How Pharmacy Benefit Managers Impact Prescription Drug Use Presented by Daniel Tomaszewski Pharmd, PhD 1 Medical Vs. Pharmacy Coverage Medical Insurance Managed by an Insurance
More informationInnovative Prescription Drug Management from Great-West Life
Issue 1 June 2011 Innovative Prescription Drug Management from Great-West Life Is your plan keeping pace? Prescription drug benefits play a significant role in the overall health and well-being of your
More informationInnovative Prescription Drug Management from Great-West Life
Issue 1 Innovative Prescription Drug Management from Great-West Life Is your plan keeping pace? Prescription drug benefits play a significant role in the overall health and well-being of your employees,
More informationDynamic Therapeutic Formulary (DTF) A Tiered Drug Plan
Dynamic Therapeutic Formulary (DTF) A Tiered Drug Plan Our tiered DTF drug plan is designed to help you manage drug costs while preserving plan member choice. a two-tiered drug plan. With this approach,
More informationSESSION/SÉANCE : 10 - Large Amount Drug Pooling Mechanism and Cost Drivers. SPEAKER(S)/CONFÉRENCIER(S) : Stephen Frank
SESSION/SÉANCE : 10 - Large Amount Drug Pooling Mechanism and Cost Drivers SPEAKER(S)/CONFÉRENCIER(S) : Stephen Frank AGENDA Rationale for this agreement Benefits for Canadians How the agreement works
More informationALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST SUBMISSIONS for DRUG REVIEWS
SUBMISSIONS for DRUG REVIEWS 1) Only submissions satisfying all of the submission requirements of the applicable category of drug product that are deemed complete by the applicable submission deadline
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationRecommendations on Proposed Amendments to the Patented Medicines Regulations
Page 1 Recommendations on Proposed Amendments to the Patented Medicines Regulations June 28, 2017 Endorsed By: CONECTed Collective Oncology Network for Exchange, Cancer Care, Innovation, Treatment Access
More informationRetrospective Data Trends and National Benchmarks
Retrospective Data Trends and National Benchmarks Shawn O Brien Principal TELUS Health Content outline I. Terminology and background II. Key results III. Drug type utilization IV. Specialty drug analysis
More informationTELUS Talks Health. The drug pipeline paradigm shift Game-changing therapies: who pays? The new therapeutic paradigm. March 2016 Edition
TELUS Talks Health The drug pipeline paradigm shift Game-changing therapies: who pays? March 2016 Edition Author, Luc Vilandré, Vice-President and General Manager, Health Benefits and Payment Solutions
More informationManaging Specialty Pharmaceuticals: Balancing Access and Affordability
Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President
More informationESI Canada 2003 Drug Trend Report
ESI Canada 2003 Drug Trend Report Drug costs rise 9% to $20 billion in 2003, predicted to reach $30 billion by 2010. 2003 Drug Trends and a Glimpse into the Future On the minds of many plan sponsors are
More informationFederal Cost of a National Pharmacare Program
Federal Cost of a National Pharmacare Program Ottawa, Canada 28 September 2017 www.pbo-dpb.gc.ca The mandate of the Parliamentary Budget Officer (PBO) is to provide independent analysis to Parliament on
More informationStanding strong for payers and patients
Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE
More informationRetiree Health Insurance Plan
Retiree Health Insurance Plan NEW RATES AND PLAN CHANGES BEGINNING JANUARY 1, 2016 E very dollar counts, especially when you are a retiree. Whether you are buying your groceries or planning a trip, getting
More informationThe Cost of Specialty Drugs: Payer Perspectives
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important
More informationJune 28, 2017 SUBMISSION
June 28, 2017 SUBMISSION CONSULTATION DOCUMENT, PROTECTING CANADIANS FROM EXCESSIVE DRUG PRICES PATENTED MEDICINE PRICES REVIEW BOARD (PMPRB) AND THE PATENTED MEDICINES REGULATIONS 55 rue Metcalfe Street
More informationMoving From Offers to Solutions
Moving From Offers to Solutions ALIGN CHANNEL STRATEGIES WITH PATIENT NEEDS TO REDUCE ACCESS BARRIERS Doug Gabbard The views and opinions expressed and presented here are my own and do not reflect the
More informationMANAGEMENT ENTRY STRATEGIES: SPAIN S CASE
7th European Pharma Licensing Symposium 23rd & 24th September 2014 MANAGEMENT ENTRY STRATEGIES: SPAIN S CASE GENERAL OVERVIEW MARKET ARMONIZATION: DECLARED AS A PRIORITY. CENTRAL GOVERNMENT INTENDS TO
More informationBrief on Fair Drug Prices in New Brunswick
Brief on Fair Drug Prices in New Brunswick New Brunswick Association of Social Workers Ensuring quality professional social work services to the population of New Brunwick August 12, 2011 1-877-495-5595
More informationERM , Getzen Economics and Financing (Sec. 5.4, 5.5)
ERM 512-13, Getzen (Sec. 5.4, 5.5) 1/17 Key Points Types of Managed Care Plans Ways to Reduce Costs Features of Managed Care Utilization Review 2/17 Managed Care Plans Why Managed Care? Primary reason
More informationDrug Reimbursement - Croatia. Roganovic Jelena
Drug Reimbursement - Croatia Roganovic Jelena Population: 4,292,095 (July 2017) Area: 56,594 km 2 Density: 75.8/km 2 21 counties http://www.lokalniizbori.com/wp-content/uploads/2013/04/hrvatska-%c5%beupanije.jpg;
More informationALBERTA DRUG BENEFIT LIST
SUBMISSIONS FOR DRUG REVIEWS Only submissions satisfying all of the submission requirements of the applicable category of Drug Product that are deemed complete by the applicable submission deadline date
More informationCWAG Prescription Drug Pricing Webinar
CWAG Prescription Drug Pricing Webinar January 9, 2018 Kipp Snider, J.D. Vice President, State Policy Pharmaceutical Research & Manufacturers of America (PhRMA) Medicines Are Expected to Account for a
More informationASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? Drew Baker GO FROM HERE?
ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? An ISPOR Issue Panel by the Value Assessment of Medical Devices Working Group of the Medical Device and
More informationTOWARDS APPROPRIATE AND SUSTAINABLE ACCESS TO DRUGS FOR RARE DISEASES (DRDs): WHERE ARE WE NOW IN CANADA AND WHAT CAN WE LEARN FROM ABROAD?
TOWARDS APPROPRIATE AND SUSTAINABLE ACCESS TO DRUGS FOR RARE DISEASES (DRDs): WHERE ARE WE NOW IN CANADA AND WHAT CAN WE LEARN FROM ABROAD? Tania Stafinski, MSc, PhD Dev Menon, MHSA, PhD Derek Clark, BScN,
More informationSelectHealth Prescriptions
SelectHealth Prescriptions pharmacy benefit management program SM SelectHealth Prescriptions is a full-service Pharmacy Benefit Manager (PBM) that offers transparent pricing, clinically based programs,
More informationThe Canadian Pharmacists Association Response to Proposed Regulation Changes under the Drug Interchangeability and Dispensing Fee Act (DIDFA)
Helen Stevenson Executive Officer of Ontario Public Drug Programs and Assistant Deputy Minister Ministry of Health and Long-Term Care 80 Grosvenor Street, 9 th Floor Hepburn Block, Queen s Park Toronto,
More informationCommon Managed Care Terms & Definitions
Contact Us: Email: info@emedbiz.com Phone: 561-430-2090 Fax: 561-430-2091 Website: www.emedbiz.com Common Managed Care Terms & Definitions Balance billing: The practice of billing a patient for the amount
More informationPacific Blue Cross. Pacific Blue Cross and BC Life are represented by CUPE local 1816.
Pacific Blue Cross Pacific Blue Cross is a not-for-profit organization our resources are used to serve stakeholders, not stockholders. financial surpluses are reinvested into the business for the current
More informationManion Magazine. Employment Standards Changes Regarding Proposed Bill 148. Inside This Issue
Manion Magazine VOLUME 4 ISSUE 3 JULY 2017 Inside This Issue 1 Employment Standards Changes Regarding Proposed Bill 148 2 WSIB Changes To Include Coverage For Chronic Mental Stress In The Workplace 2 Alberta
More informationPublic and Private Payer Responses to Pharmaceutical Pricing in the United States
Public and Private Payer Responses to Pharmaceutical Pricing in the United States James C. Robinson Leonard D. Schaeffer Professor of Health Economics Director, Berkeley Center for Health Technology University
More informationRe: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]
January 25, 2019 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P P.O. Box 8013 Baltimore, MD 21244-8013 Re: Modernizing
More informationWorkers Compensation Board Pharmacy Benefit Plan
1.0 Introduction Workers Compensation Board Pharmacy Benefit Plan Options for pharmaceutical care have greatly expanded over the past several years. New pharmaceuticals and pharmaceutical treatment modalities
More informationDraft Released: February 1, Final Released: April 2, Effective Date: January 1, 2019
AMCP Summary: Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter Draft Released: February 1, 2018 Final
More informationReport. Extended Healthcare and Dental Experience: A Report on a Post-employment Benefits Experience Study
Report Extended Healthcare and Dental Experience: A Report on a Post-employment Benefits Experience Study Group Life and Health Subcommittee of the CIA Research Committee Prepared by: Have Associates March
More informationCompass. 3 rd Edition. Annual Public Drug Plan Expenditure Report 2015/16
Compass 3 rd Edition Annual Public Drug Plan Expenditure Report 2015/16 Published by the Patented Medicine Prices Review Board May 2017 CompassRx, 3 rd edition: Annual Public Drug Plan Expenditure Report,
More informationApril 8, 2019 VIA Electronic Filing:
April 8, 2019 VIA Electronic Filing: http://www.regulations.gov The Honorable Alex Azar Secretary Department of Health and Human Services 200 Independence Avenue SW, Room 600E Washington, D.C. 20201 Re:
More informationAligning regulatory incentives for innovation in the consumer health products industry
Aligning regulatory incentives for innovation in the consumer health products industry Canada-European Union Comprehensive Economic and Trade Agreement Regulatory Cooperation Forum Submitted to the Treasury
More informationGENERIC DRUG PRICING AND ACCESS IN CANADA: WHAT ARE THE IMPLICATIONS?
GENERIC DRUG PRICING AND ACCESS IN CANADA: WHAT ARE THE IMPLICATIONS? A commissioned discussion paper by SECOR Consulting. JUNE 2010 TABLE OF CONTENTS 02 Foreword 03 Introduction 04 Executive Summary 07
More informationConsultations. Board s Excessive Price Guidelines
Patented Medicine Prices Review Board Released May 2006 Discussion Guide for the Consultations on the Board s Excessive Price Guidelines Patented Medicine Prices Review Board Box L40 Standard Life Centre
More informationAffordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011
Affordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011 Executive Summary and Recommendations The MS Society of Canada, Atlantic Division
More informationProtecting the Health of New Brunswickers
Pharmasave Drugs Atlantic Ltd. is pleased to provide this submission as part of the consultation process for the New Brunswick government s Fair Drug Prices for New Brunswickers. The New Brunswick government
More informationECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY. Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx
ECONOMIC PRINCIPLES IMPACTING MANAGED CARE PHARMACY Adrian Washington PharmD., MBA Vice President of Client Management United Healthcare OptumRx As vice president, Adrian is responsible for strategic planning
More informationBudget Impact Analysis Guidelines. Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
Patented Medicine Prices Review Board Conseil d examen du prix des médicaments brevetés npduis Rx Budget Impact Analysis Guidelines Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission
More information21 - Pharmacy Services
21 - Pharmacy Services The role of Health Plan of Nevada s (HPN) Pharmacy Services is to evaluate and determine the appropriateness of quality drug therapy while maintaining and improving therapeutic outcomes.
More informationProviders Contracting Directly With Employers
Providers Contracting Directly With Employers NOVEMBER 14, 2018 1 The Current Model 2 Direct-to-Employer (DTE) Health Plan Aligned Incentives Gain Share Direct Relationship At The Table Integrated Data
More informationNews & Views. Knowledge & Insights. Ontario delays ORPP. Volume 13 Issue 3 March In this issue
Knowledge & Insights News & Views Volume 13 Issue 3 March 2016 In this issue 1 Ontario delays ORPP 2 Ontario Budget 2016: pension and benefits related measures 4 BC: changes to health premiums 5 Ontario:
More informationGLOSSARY. MEDICAID: A joint federal and state program that helps people with low incomes and limited resources pay health care costs.
GLOSSARY It has become obvious that those speaking about single-payer, universal healthcare and Medicare for all are using those terms interchangeably. These terms are not interchangeable and already have
More informationA look at what happened and its impact on group benefits plans
Legislation in 2007 A look at what happened and its impact on group benefits plans January 24, 2008 (#131) Federal and provincial legislation can have a considerable impact on group benefits plans. Here
More informationIntroduction to the US Health Care System. What the Business Development Professional Should Know
Introduction to the US Health Care System What the Business Development Professional Should Know November 2006 1 Understanding of the US Health Care System Evolution of the US health care system to its
More informationRISK SHARE AGREEMENTS
THIRD PLENARY: Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned Gergana Zlateva Pfizer Inc New York, NY, USA RISK SHARE AGREEMENTS Gergana Zlateva, PhD VP, Global Market Access
More informationOntario English Catholic Teachers Association Employee Life and Health Trust 1
Ontario English Catholic Teachers Association Employee Life and Health Trust Plan Document Number: G0205002 Group Policy Number: G0105002 Plan A: Teachers Member Name: OTIP Identification Number: Welcome
More informationThank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.
Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need. Did you know that NeedyMeds has thousands of other free resources?
More informationIt takes a village. Sustainable drug plans that reduce spend; not access
TELUS Talks Health April 2017 Edition It takes a village. Sustainable drug plans that reduce spend; not access Luc Vilandré, Vice President and Chief Operating Officer Karen Kesteris, Director of Payor
More informationTrillium Drug Program Questions and Answers for Cancer Patients in Ontario 1
Trillium Drug Program Questions and Answers for Cancer Patients in Ontario 1 The Trillium Drug Program Q1. What programs can help me pay for my cancer drugs? A1. The Ontario Drug Benefit (ODB) Program
More informationChallenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare
Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning
More informationDrug Coverage Programs for Patients with Cancer
Drug Coverage Programs for Patients with Cancer Information for patients and families Read this guide to learn about: different drug coverage programs which program to use and how to use it who to contact
More informationSecond Phase of Alberta Pharmaceutical Strategy announced
W I N T E R 2 0 1 0 Second Phase of Alberta Pharmaceutical Strategy announced In late October 2009, the Government of Alberta announced Phase Two of the Alberta Pharmaceutical Strategy, a plan to make
More informationIssue brief: Medicaid managed care final rule
Issue brief: Medicaid managed care final rule Overview In the past decade, the Medicaid managed care landscape has changed considerably in terms of the number of beneficiaries enrolled in managed care
More informationIn This Issue (click to jump):
May 7, 2014 In This Issue (click to jump): Analysis of Trends in Health Spending 2013 2014 Spotlight on Medicare Advantage Enrollment Oncology Drug Trend Report S&P Predicts Shift from Job-Based Coverage
More informationShare a Clear View. El Paso Children's Hospital. Printed on:
Share a Clear View El Paso Children's Hospital Printed on: Share a Clear View NAVITUS CUSTOMER CARE HOURS: 24 Hours a Day 7 Days a Week 855-673-6504 (toll-free) TTY (toll-free) 711 MAILING ADDRESS: Navitus
More informationDisease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry
Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Jeffrey A. Bourret, M.S., R.Ph., FASHP Senior Director, Managed Markets Healthcare Systems Marketing
More informationPayer Channel Forecasting and Analysis. Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc.
Payer Channel Forecasting and Analysis Patrick J. Park, PharmD, MBA Director, Business Decision Support Daiichi Sankyo, Inc. Disclaimer The views and opinions expressed in this presentation are those of
More informationMcKesson Corporation J.P. Morgan Healthcare Conference
McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in
More information2017 EMPLOYER SERIES. 6 Things Employers Need to Know About Rising Health Care Costs. Cost Management Key Findings
2017 EMPLOYER SERIES 6 Things Employers Need to Know About Rising Health Care Costs Cost Management 2017 Key Findings It s one of the biggest challenges employers face today: keeping health care costs
More informationThis document contains both information and form fields. To read information, use the Down Arrow from a form field.
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Prior Authorization, Pharmacy and Health Case Management Information The purpose of this
More informationFair Drug Prices for New Brunswickers. Submitted By: The New Brunswick Union of Public and Private Employees
Fair Drug Prices for New Brunswickers Submitted By: The New Brunswick Union of Public and Private Employees 15 August 2011 The New Brunswick Union of Public and Private Employees (the New Brunswick Union),
More informationSubject: Pharmacy Services & Formulary Management (Page 1 of 5)
Subject: Pharmacy Services & Formulary Management (Page 1 of 5) Objective: I. To ensure the clinically appropriate prescription and use of pharmaceuticals by Tuality Health Alliance (THA) providers and
More informationPharmacy Program Management: Pitfalls, Challenges, and Best Practices About Solid Benefit Guidance specialty 60,000,000 covered member lives INSIDER
Pharmacy Program Management: Pitfalls, Challenges, and Best Practices October 2, 2017 This presentation contains proprietary information and is not to be reproduced or further distributed without permission
More informationWhat s Inside PHARMACARE THESE DAYS EVERYONE S TALKING ABOUT PHARMACARE PAGE 2 WHAT S UP... PAGE 8 JULY/AUGUST greenshield.
JULY/AUGUST 2018 What s Inside A N D N O W F O R S O M E T H I N G ICYMI: Stephen Frank, president and CEO of the Canadian Life and Health Insurance Association, talks pharmacare in episode five of our
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More information